07:00 , Aug 3, 2009 |  BC Week In Review  |  Company News

Argolyn neurology news

Argolyn filed for Chapter 7 bankruptcy after the company determined its lead candidate for pain was not potent enough to continue development. The company's preclinical pipeline of neurotensin derivatives included ABS212 for pain. Argolyn Bioscience...
07:00 , Mar 17, 2008 |  BC Week In Review  |  Company News

Argolyn management update

Argolyn Bioscience Inc. , Research Triangle Park, N.C.   Business: Neurology   Hired: M. Nixon Ellis as president and CEO; and George Koszalka as chief development officer  ...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Company News

Argolyn board of directors update

Argolyn Bioscience Inc. , North Charleston, S.C.   Business: Neurology   Appointed: Dennis Dougherty, a founding general partner at Intersouth Partners; and Geeta Vemuri, a principal at Quaker BioVentures  ...
07:00 , Jul 2, 2007 |  BioCentury  |  Finance

Calling card put away

When GlaxoSmithKline gained an exclusive option in 2004 to all of Theravance's programs through August 2007, the initial worry among investors was that THRX had become a hostage to the pharma giant. That turned out...
01:07 , Jun 26, 2007 |  BC Extra  |  Financial News

Argolyn raises $15.8 million

Neurology company Argolyn (North Charleston, S.C) raised $15.8 million in a series A1 round led by Intersouth Partners and Quaker BioVentures. Amgen Ventures also participated. Argolyn is developing two preclinical neurotensin derivatives: ABS201 to treat...
07:00 , Aug 19, 2002 |  BC Week In Review  |  Company News

Paradigm management update

Paradigm Genetics Inc. (PDGM), Research Triangle Park, N.C.   Business: Functional genomics   Hired: Thomas Colatsky as VP of healthcare research, formerly president and CEO of Argolyn Bioscience  ...